MSFrontier

Confirmed

One controlled phase 3 trial met its main goal, and teriflunomide is approved for this use.

DHODH inhibition (pyrimidine synthesis): reduce relapses and new lesions in relapsing and progressive MS

Trial timeline

Phase 320042022

Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.

relapsing and progressive MS · DHODH inhibition (pyrimidine synthesis)

Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.

Trials
5
Running now
3
Controlled phase 2/3 trials
3
People in controlled trials
3309

Deciding trials (phase 3): 1 met, 0 did not.

Other linked trials: 4

Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.

Trials

  • ENSURE-2decides the statusOngoing

    Phase 3 · 2022 · Placebo-controlled · MSFT-NCT05201638

  • ENSURE-1decides the statusOngoing

    Phase 3 · 2021 · Placebo-controlled · MSFT-NCT05134441

  • TEMSOdecides the statusMet main goal

    Phase 3 · 2004 · Placebo-controlled · MSFT-NCT00134563

Other linked trials: 4

These linked trials do not set the status.

  • DESIRE MSOngoing

    Phase 3 · 2026 · Compared with ocrelizumab, ofatumumab, rituximab

  • DOT-MSResult in a paper, not read yet

    Phase not applicable · 2020 · Not randomised

The deciding phase and counts come from the Trial Bank’s fixed rules.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

  • 2026-10-27First listed as Confirmed

Related hypotheses

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error